Escitalopram: better treatment for depression is through the looking glass

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2004-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1586/14737175.4.5.769PMID 15853504
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug Chirality and its Clinical Significance

  2012cited by this paper
• A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder.

  2005cited by this paper
• Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.

  2003cited by this paper
• An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir.

  2003cited by this paper
• Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.

  2003cited by this paper
• The use of antidepressants in novel combination therapies.

  2003cited by this paper
• Escitalopram

  2003cited by this paper
• Clinical correlates of inpatient suicide.

  2003cited by this paper
• Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo‐controlled study in depression in primary care

  2003cited by this paper
• Escitalopram: What Does it Have to Offer?

  2003cited by this paper
• The 12th world congress of psychiatry.

  2003cited by this paper
• Effectiveness of antidepressants: comparative remission rates.

  2003cited by this paper
• The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

  2003cited by this paper
• Escitalopram prevents relapse of depressive episodes

  2002cited by this paper
• Escitalopram 10mg/day is e¡ective and well tolerated in a placebo-controlled study in depression in primary care

  2002cited by this paper
• Efficacy Comparison of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: Pooled Analysis of Placebo-Controlled Trials

  2002cited by this paper
• Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain.

  2002cited by this paper
• Stereoisomers in Psychiatry: The Case of Escitalopram.

  2002cited by this paper
• Escitalopram is a new and highly efficacious SSRI in the treatment of major depressive disorder

  2002cited by this paper
• Depression in primary care patients: Improvement during long-term escitalopram treatment

  2002cited by this paper
• Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.

  2002cited by this paper
• The economic and social burden of depression.

  2001cited by this paper
• Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.

  2001cited by this paper
• Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.

  2001cited by this paper
• Depression: the relevance of the time factor.

  2001cited by this paper
• Pharmacology of rapid-onset antidepressant treatment strategies.

  2001cited by this paper
• Depression: the relevance of the time factor.

  2001cited by this paper
• Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model.

  2001cited by this paper
• Depression in patients with cardiac disease: a practical review.

  2000cited by this paper
• 292. The antidepressant activity of citalopram resides in the S- enantiomer (Lu 26-054)

  2000cited by this paper
• 296. Childhood cognitive functioning in adult patients with affective illness and their siblings

  2000cited by this paper
• Measuring antidepressant prescribing practice in a health care system using administrative data: implications for quality measurement and improvement.

  2000cited by this paper
• The Use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial1

  2000cited by this paper
• Chiral switches.

  2000cited by this paper
• Chirality and Drugs Used in Psychiatry: Nice to Know or Need to Know?

  1999cited by this paper
• Comparison of the Effects of Antidepressants and Their Metabolites on Reuptake of Biogenic Amines and on Receptor Binding

  1999cited by this paper
• Citalopram

  1997cited by this paper
• Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation

  1997cited by this paper
• Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.

  1997cited by this paper
• Pharmacological profile of antidepressants and related compounds at human monoamine transporters.

  1997cited by this paper
• Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.

  1997cited by this paper
• Comorbidity of DSM–III–R Major Depressive Disorder in the General Population: Results from the US National Comorbidity Survey

  1996cited by this paper
• Social phobia.

  1995cited by this paper
• Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror

  1995cited by this paper
• The D3 receptor and its relevance in psychiatry

  1995cited by this paper
• Stereochemical determinants of the nature and consequences of drug metabolism.

  1995cited by this paper
• Stereochemical Aspects of Pharmacotherapy

  1995cited by this paper
• Long-term treatment of depression

  1994cited by this paper
• Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.

  1993cited by this paper
• The economic burden of depression in 1990.

  1993cited by this paper
• Prevalence of Depression in Adults With Diabetes: An epidemiological evaluation

  1993cited by this paper
• Enantiomers: implications and complications in developmental pharmacology.

  1992cited by this paper
• Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors.

  1991cited by this paper
• Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor.

  1988cited by this paper
• Social phobia.

  1987cited by this paper
• The economic burden of depression.

  1986cited by this paper
• The Anxiety Disease

  1984cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• Assessing depressive symptoms in five psychiatric populations: a validation study.

  1977cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper
• The assessment of anxiety states by rating.

  1959cited by this paper

• Gastrointestinal Tolerability and Absorption of R‐ Versus R,S‐Lipoic Acid in Progressive Multiple Sclerosis: A Randomized Crossover Trial

  2020cites this paper
• The effectiveness of high-dose escitalopram in the treatment of patients suffering from schizophrenia with comorbid obsessive-compulsive disorder: an open-label study.

  2019cites this paper
• Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial

  2016cites this paper
• Regulating the Skin Permeation Rate of Escitalopram by Ion-pair Formation with Organic Acids

  2016cites this paper
• Escitalopram in the treatment of patients with schizophrenia and obsessive–compulsive disorder: an open-label, prospective study

  2013influential citation
• Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: a model of comorbid depression and anxiety?

  2009cites this paper
• Mechanism of action of antidepressants: aspects of serotoninergic system and its interaction with glutamate

  2006cites this paper